You are here: Industry Insights > gilead

News List

Gilead and Novo Nordisk’s NASH trial meets primary endpoint pharmatimes
November 18, 2020
Gilead and Novo Nordisk have announced that a phase II proof-of-concept trial evaluating combination treatments for non-alcoholic steatohepatitis (NASH) met its primary endpoint.
Flamma Continues Veklury Partnership with Gilead for Covid-19 americanpharmaceuticalreview
November 16, 2020
Flamma entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury® (remdesivir) supply chain.
Gilead Bolsters Biologics Capabilities contractpharma
November 11, 2020
ProteoNic, a provider of technology and services for efficient production of biologics, has licensed its premium 2G UNic technology for boosting therapeutic protein production to Gilead Sciences.
Flamma, Gilead Continue Mfg. Partnership for Veklury contractpharma
November 09, 2020
Flamma will continue to use its sites in Italy and China to support Gilead's network of manufacturers contributing to supply of Veklury.
Gilead gets USFDA approval for Veklury (remdesivir) to treat COVID-19 expresspharma
October 26, 2020
Gilead Sciences announced that the US Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalisation.
EC signs agreement for additional doses of Gilead’s Covid-19 drug pharmaceutical-technology
October 10, 2020
The European Commission (EC) has inked a joint procurement agreement (JPA) with Gilead Sciences for the supply of up to 500,000 treatment courses of the company’s Covid-19 drug, Veklury (remdesivir).
Gilead’s oral JAK inhibitor filgotinib wins EU approval pharmatimes
September 30, 2020
Gilead Science’s Galapagos-partnered oral JAK inhibitor filgotinib has been approved by the European Commission under the brand name Jyseleca for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
Gilead gets approval for Jyseleca (filgotinib) in Japan for rheumatoid arthritis expresspharma
September 27, 2020
Gilead Japan will hold marketing authorisation of Jyseleca in Japan while Eisai will be responsible for product distribution.
Gilead may soon buy Immunomedics in deal over $20 billion expresspharma
September 24, 2020
The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports.
Gilead gets FDA breakthrough therapy status for magrolimab in MDS pharmaceutical-business-review
September 18, 2020
Gilead Sciences has been given breakthrough therapy designation for magrolimab from the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) in newly diagnosed patients.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page